Kakao Leisure units a brand new world normal with the launch of ‘KAKAO WEBTOON’


Billionaire Israel Englander is betting on these 2 penny stocks

Let’s talk about risk, reward, and pennies. The three are of course related. There is no reward in the stock market without taking some risk – and penny stocks offer investors an optimal combination of both. The “pennies” are the cheapest stocks in the public markets, typically selling for less than $ 5 per share. With a stock price this low, even a small profit – an increase in the stock price by just a few cents – can quickly lead to a high percentage return. However, there is one but here. The critics point out that there could be a reason for the low price, whether it be poor fundamentals or overwhelming headwinds. So how are investors supposed to determine which penny stocks are ready to make them big? Tracking the activity of the investing titans is one strategy. Step into Israel “Izzy” Englander, well known for his formidable stock picking skills. Englander showed an interest in the stock market since his youth and founded the hedge fund Millennium Management together with Ronald Shear in 1989. Using a wide range of strategies spanning a variety of mostly liquid asset classes, Englander was able to turn the $ 35 million used to launch the fund into a Wall Street giant of over $ 45 billion. With an estimated net worth of $ 9.6 billion in 2021, it’s no wonder Wall Street’s focus is on the guru when he takes a step. With all of this in mind, we used TipRanks’ database to take a closer look at two Penny stocks that Englander recently bought. The platform found that both buy-rated tickers were also endorsed by some members of the analyst community. T2 Biosystems (TTOO) We start in the healthcare industry where T2 Biosystems is working to revolutionize diagnostics. The company offers diagnosticians and medical laboratories a range of devices based on T2MR (T2 Magnetic Resonance) technology to diagnose a wide variety of septic diseases quickly and accurately. The company notes that sepsis kills more people each year than AIDS, breast cancer and prostate cancer combined. Quick and accurate diagnosis is key to patient survival, and this is the niche that T2 seeks to fill. The company’s technology enables diagnostic blood tests with results available in a matter of hours compared to the 1 to 5 days currently required by most medical laboratory tests. Available test products include the T2Bacteria Panel and T2Candida Panel, which are the only FDA-approved blood tests for septic agents that do not have to wait for a blood culture. A T2SARS-CoV-2 panel of upper airway samples is also available. T2 has an active pipeline of rapid diagnostic tests for a wide variety of diseases. Upcoming products include the T2Cauris panel and the T2Resistance panel. These test products are currently for Research Use (ROU) only in the United States. The T2Lyme panel, which enables faster diagnosis of difficult-to-diagnose Lyme disease, is at an earlier stage of development. All T2 products work with the same T2Dx instrument and thus enable interchangeability in the laboratory environment. The device offers a simple user interface and works with only 4 ml of whole blood. T2 boasts that its device is used in more than 200 hospitals around the world. In the first quarter of 2021, T2 revenue increased 173% year over year to $ 7 million. This was due to product sales increasing 345% year over year to $ 4.7 million. US sepsis test utilization increased 85% in the quarter year over year, showing increased adoption of the device and technology. Izzy Englander is among those who have high hopes for this name in healthcare. In the first quarter, Englanders Millennium raised over 1.36 million TTOO shares valued at $ 1.5 million. This increased Englander’s stake in the company to 2.68 million shares with a market value of $ 2.9 million. Canaccord’s 5-star analyst Charles Duncan is also a fan. Duncan gives TTOO shares a buy rating along with a price target of $ 3.50. This goal conveys his confidence in TTOO’s ability to grow 212% over the next twelve months. (To see Duncan’s track record, click here.) “T2 revenue growth of + 345% year over year is a positive starting point for the company’s post-pandemic business strategy, supported by scaling to close to 10 direct sales reps in the first quarter . We view the acquisitions of Cepheid, BioFire, GenMark and Luminex as confirmation that the hospital laboratory is an attractive industry segment as clinicians (and patients) desire to move from centralized testing strategies to a more decentralized approach. With these four companies off the table, T2 should benefit from the scarcity value. Regardless, a more aggressive approach to commercial execution should go well with increasing awareness of antibiotic resistance and sepsis in a post-pandemic environment where diagnosis of infectious diseases is a priority, “noted Duncan. It turns out that other analysts have high hopes With 4 buys and a single hold, the word on the street is that this stock, currently trading at $ 1.10 each, is a strong buy, and its average target price of $ 2.83 gives upside potential 156% (see TTOO stock analysis) TipRanks) Sesen Bio (SESN) The second stock we’ll look at, Sesen Bio, is a pharmaceutical company. Sesen works in cancer treatment and develops antibody-drug conjugate therapies. The result is a single protein molecule that kills cancer cells with minimal toxic effects on the body – a complementary response from the patient ten stimulates the natural immune system. Sesen’s pipeline currently includes a drug candidate, Vicineum, which is being tested for multiple lanes at the same time. The main avenue that has completed clinical trials and initiated the Biological License Application (BLA) submission process is through the treatment of non-muscle invasive bladder cancer. The BLA was approved for filing by the FDA last February, and the company is on track for possible approval on August 18, 2021. European approval of Vicineum for the treatment of bladder cancer is expected in early 2022. The company’s other pipeline projects are earlier stages. Vicineum is currently being investigated for the treatment of head and neck cancer and is in phase 2 trials. Other traces of investigation are still in the pre-clinical stage. Clinical stage biopharmaceutical companies are always very speculative, and in this case Englander didn’t mind speculating. In the first quarter, his company bought 987,926 shares of SESN, increasing its stake in the company by 156%. Englander’s stake in Sesen now stands at $ 2.9 million. 5-star analyst Swayampakula Ramakanth, who deals with SESN for HC Wainwright, also sees an opportunity. “Given Vicineum’s favorable risk-benefit profile demonstrated in the Phase 3 VISTA trial, we believe the drug has a high likelihood of gaining regulatory approvals from the FDA and EMA. Sesen is preparing We have selected Syneos, a leading contract sales organization, as part of building and managing a 35-strong sales team to reach approximately 2,000 high-prescription BCG patients. We expect the drug to be available immediately We expect Vicineum to be risk-adjusted. Revenue of $ 516 million by 2030E increased from $ 9 million in 2021E, “said Ramakanth. Ramakanth’s comments support his buy recommendation for the stock as well as his price target of $ 8. At current valuations, this target implies an upside potential of 170% over the next 12 months. (To see Ramakanth’s track record, click here.) Sometimes the penny stocks can slip under the radar. This has only attracted two recent analyst reviews. However, both agree that this is a stock to buy, which makes the consensus on moderate buy unanimous. The shares are priced at $ 2.94 with an average target price of $ 7.50, indicating an upward movement of 155% over the coming year. (See SESN Stock Analysis on TipRanks.) To find great ideas for trading penny stocks at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that brings together all of the insights into TipRanks stocks. Disclaimer: The opinions expressed in this article are solely those of the presented analysts. The content is intended to be used for informational purposes only. It is very important that you do your own analysis before making any investment.

Launch of KAKAO ENTERTAINMENT by means of strategic merger of Kakao Web page and Kakao M

The combination of Kakao Page and Kakao M means creating a Korean entertainment giant that is about to generate KRW 1 trillion in annual revenue. At a time when the global entertainment industry is facing tough competition due to the appearance of new players in the industry, this strategic merger was decided to give KAKAO ENTERTAINMENT a competitive advantage in the market. This is also the first large-scale merger between the subsidiaries of Kakao Corp., the technology conglomerate behind Korea’s most popular messaging app, Kakao Talk.

The merger of Kakao Page and Kakao M is expected to create a robust synergy effect given the capabilities of the respective companies in the content business and on digital platforms and lay the foundation for KAKAO ENTERTAINMENT’s next growth phase through global expansion.

Through the merger, KAKAO ENTERTAINMENT will have an unparalleled business portfolio and value chain, including 50 subsidiaries and affiliates in all sectors of the entertainment industry. Kakao Page offers a special value chain that is optimized for both the creation of original content and the creation of original content a global platform network, while Kakao M offers expertise in creating music, TV series, films, performances as well a Portfolio of Korea’s best creative talent.

With this foundation, KAKAO ENTERTAINMENT will expand its investments and strategic partnerships with industry leaders to develop into a global entertainment company. In addition to diversifying its business, the company will focus on producing blockbuster media franchises that will captivate global audiences and look for various ways to create synergies between combined assets.

Kakao Page commented: “The merger of Kakao Page and Kakao M is that of a strategic alliance to build a foundation for competition in the global entertainment industry. By combining the two companies’ business acumen, skills and value chain, we aim to disrupt the global entertainment industry. “

Kakao M commented: “The decision to combine our expertise in content and digital platforms was made so that we can seriously compete in the highly competitive global entertainment sector. Together we can accelerate and develop into a global player.”

About Cocoa Page Corp.

Cocoa Page Corp. specializes in creating compelling IPs for stories, mainly in the form of webtoons and web novels. The company pioneered the Korean story entertainment industry in 2014 with an innovative monetization model called “Wait or Pay”. In addition to this growth model, the company’s active investment in 16 subsidiaries and affiliates paved the way for Kakao Page Corp. highest number of original titles in Korea (8,500 IPs). The company operates two digital platforms in Korea, the “Kakaopage” platform of the same name and the world’s first Webtoon platform called “Daum Webtoon”. The company also has widespread global platform networks in Japan, North America, Greater China and ASEAN regions. The original content of Kakao Page Corp. have been converted into various derivative formats such as TV series, movies, games and are popular in too Japan, the world’s largest comic book market, and in North America Regions.

About Kakao M Corp.

Cocoa M Corp. has unrivaled production capacity for content on mobile, TV, screen and live platforms with 7 leading talent management subsidiaries, 4 music labels and various production companies for drama, film and performance. Cocoa M Corp. has a significant market share in the Korean music industry and produces over 1,200 tracks annually. In addition, the company has 80 top creators, 150 celebrities and a large number of star producers in its talent portfolio. Kakao M also runs its own studio recruiting Korea’s most wanted producers and operate a new genre of experimental and fun mobile content.

SOURCE Cocoa Page Corp.

Launch of KAKAO ENTERTAINMENT by strategic merger of Kakao Web page and Kakao M


3 top dividend stocks with growth opportunities; Goldman Sachs Says “Buy”

Investing is about making a profit, and investors have long seen two main paths towards that goal. Growth stocks, stocks that generate a return based primarily on the appreciation of the stock price, is one way. The second route is through dividend stocks. These are stocks that pay back a percentage of profits to shareholders – a dividend that is usually paid quarterly. Payments vary widely from less than 1% to more than 10%, but the average among stocks listed on the S&P 500 is around 2%. Dividends are a nice addition for a patient investor as they provide a steady stream of income. Goldman Sachs analyst Caitlin Burrows has looked into the real estate trust segment, a group of stocks long known for high and reliable dividends – and she sees many reasons to expect strong growth in three stocks in particular. As we led the trio through TipRanks’ database, we learned that all three were cheered on by the rest of the street as well, as they have an analyst consensus of “Strong Buy”. Broadstone Net Lease (BNL) First off, Broadstone Net Lease is an established REIT that went public last September and grossed over $ 533 million. The company launched 33.5 million shares, followed by another 5 million shares, which were acquired by subscribers. It was viewed as a successful opening and BNL now has a market cap of over $ 2.63 billion. Broadstone’s portfolio includes 628 properties in 41 states and the Canadian province of British Columbia. These properties have 182 tenants and are valued at $ 4 billion. The best feature here is the long-term nature of the leases – the weighted average remaining lease is 10.8 years. For the third quarter, the most recent with full financial data available, BNL posted net income of $ 9.7 million, or 8 cents per share. Most of its income came from rents, and the company said it collected 97.9% of rents due in the quarter. Looking ahead, the company expects property acquisitions of $ 100.3 million in the fourth quarter and an increased rent collection rate of 98.8%. Broadstone’s earnings and high rental income support a dividend of 25 cents per common share, or $ 1 a year. This payment is affordable for the company and offers investors a 5.5% return. Goldman’s Burrows sees the company’s acquisition moves as the most important factor. “Acquisitive acquisitions are the main earnings driver for Broadstone … While management stopped acquisitions after COVID-induced market uncertainties (BNL did not make any acquisitions in the first half of 20) and before going public, we are confident that the acquisitions will be in 2021 will begin activity in the fourth quarter of 20 … We estimate that BNL has a positive investment spread of 1.8%, resulting in earnings growth of 0.8% (to 2021E FFO) per $ 100 million acquisitions (or 4, To this end, Burrows rates BNL as a buy and their target price of $ 23 implies an uptrend of ~ 27% for the coming year. (Click to see Burrow’s track record You here.) Wall Street broadly agrees with Burrows on Broadstone, as evidenced by the 3 positive ratings the stock has received over the past few weeks the only ratings available to make the analysts’ consensus rating a unanimous strong buy. The shares are currently valued at $ 18.16 and the average target price is $ 21.33, which corresponds to a year-long upward trend of ~ 17%. (See BNL stock analysis on TipRanks.) Realty Income Corporation (O) Realty Income is a major player in the REIT space. The company has a portfolio valued at more than $ 20 billion with more than 6,500 properties in 49 states, Puerto Rico and the United Kingdom. Annual sales exceeded $ 1.48 billion in fiscal 2019 (the last with full data) and has held a monthly dividend for 12 years. If we look at the latest data, we find that O had earnings of 7 cents per share and total revenue of $ 403 million for the third quarter of 20. The company collected 93.1% of its contracted rents in the quarter. A drill down to the monthly values ​​is relatively low, but shows that the rental collection rates have increased since July. As already mentioned, O pays a monthly dividend and has done so regularly since it was listed on the stock exchange in 1994. The company increased its payout in September 2020, marking the 108th increase in that time. The current payment is 23.45 cents per common share, which equates to an annual return of $ 2.81 – and a return of 4.7%. Based on the above, Burrows has placed this stock on their Americas Conviction List with a Buy rating and a target price of $ 79 for the next 12 months. This target implies an upward movement of 32% from the current level. Burrows reiterated their stance: “We estimate FFO growth of 5.3% per annum over the period 2020E-2022E versus an average of 3.1% for full REIT coverage. We assume that the main drivers of earnings will be a sustained recovery in acquisition volume and a gradual improvement in theater rents (in 2022). The analyst added, “We expect O to make acquisitions of $ 2.8 billion each in 2021 and 2022, which is the consensus expectation of $ 2.3 billion. [We] We believe our acquisition volume assumptions may actually turn out to be conservative, given that eight days after 2021, the company has already made or approved acquisitions worth $ 807.5 million (or 29% of our 2021 estimate). “Overall, Wall Street is taking a bullish stance on Realty Income stocks. 5 buys and 1 hold issued in the past three months make the stock a strong buy. Meanwhile, the average price target indicates $ 69.80 on an upward movement of ~ 17% against the current share price (see O share analysis on TipRanks) Essential Properties Realty Trust (EPRT) Most recently, Essential Properties owns and manages a portfolio of single-tenant commercial properties in the US There are 214 tenants in more than 1,000 properties in 16 industries including car washes, convenience stores, medical services and restaurants. Essential Properties has a high occupancy rate of 99.4% for its properties. In the third quarter of 20, the company saw sales increase 18.2% over the Last year, reaching $ 42.9 million. Essential Properties F ended the quarter with an impressive amount of liquid available $ 589.4 million including cash, cash equivalents, and available credit. The strong cash position and rising sales left the company confident enough to raise its dividend for the fourth quarter. The new dividend payment is 24 cents per common share, 4.3% more than the previous payment. The current interest rate is 96 cents and gives a return of 4.6%. The company has been increasing its dividend regularly for the past two years. In her review for Goldman, Burrows focuses on the recovery Essential Properties has had since the peak of the COVID panic last year. “When protection mandates went into effect in early 2020, only 71% of EPRT’s properties were open (fully or to a limited extent). This situation has improved over the past few months and now only 1% of the EPRT portfolio is closed. We anticipate EPRT’s future earnings growth to be driven by acquisition gains and estimate 2.8% potential earnings growth from $ 100 million acquisitions, ”Burrows wrote. In keeping with their bullish approach, Burrow’s EPRT stock is rated buy and a price target of $ 26 for a year, indicating an upward trend of 27%. Overall, EPRT has 9 current analyst ratings, and the 8 buy and 1 sell breakdown gives the stock a strong buy consensus rating. The shares are priced at $ 20.46 and have an average price target of $ 22.89, which represents an upside potential of ~ 12% from current levels. (See EPRT stock analysis on TipRanks.) To find great ideas for trading dividend stocks at attractive valuations, visit TipRanks ‘Best Stocks to Buy, a newly launched tool that brings together all of TipRanks’ stock insights. Disclaimer: The opinions expressed in this article are solely those of the presented analysts. The content is intended to be used for informational purposes only. It is very important that you do your own analysis before making any investment.